Peptide Blocker of Ion Channel TRPV1 Exhibits a Long Analgesic Effect in the Heat Stimulation Model
O V Sintsova1, V A Palikov2, Y A Palikova2
1Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences, Vladivostok, Russia.
Abstract:
The ion channel TRPV1, which is one of the most important integrators of pain and inflammatory stimuli, is considered a promising therapeutic target in the treatment of pain conditions. In this work, we performed a comparative study of the analgesic effect in the "hot plate" test of recombinant analogues of Kunitz-type peptides from the sea anemone Heteractis crispa venom: APHC1-modulator of TRPV1 and HCRG21-a full blocker of TRPV1. As a result of biological tests, it was shown that the full blocker HCRG21, despite the higher value of 50% effective concentration of TRPV1 inhibition, had an equal analgesic ability with the APHC1 upon intramuscular administration and retained it for 13 h of observation. The analgesic effect of APHC1 at a dose of 0.1 mg/kg when administered intramuscularly developed very quickly in 5 min but lasted 3 h. The differences in the pharmacodynamic profile of the peptides are in good agreement with different mechanisms of binding to TRPV1.
Insights
Sea anemone peptides APHC1 and HCRG21 show comparable pain relief by targeting the TRPV1 channel. HCRG21 offers longer-lasting analgesia, while APHC1 provides rapid pain reduction, indicating distinct therapeutic potentials.
Area of Science:
- Pharmacology
- Neuroscience
- Biochemistry
Background:
- The Transient Receptor Potential Vanilloid 1 (TRPV1) channel integrates pain and inflammatory signals.
- TRPV1 is a key therapeutic target for managing pain conditions.
- Kunitz-type peptides from sea anemone venom are being explored for their pharmacological properties.
Purpose of the Study:
- To comparatively evaluate the analgesic effects of two recombinant Kunitz-type peptides, APHC1 and HCRG21, from Heteractis crispa venom.
- To investigate the impact of different TRPV1 interaction mechanisms (modulation vs. full blockade) on analgesic efficacy and duration.
- To assess the pharmacodynamic profiles of APHC1 and HCRG21 following intramuscular administration.
Main Methods:
- Comparative biological testing using the "hot plate" test in an animal model.
- Intramuscular administration of recombinant Kunitz-type peptides APHC1 (TRPV1 modulator) and HCRG21 (TRPV1 full blocker).
- Pharmacodynamic analysis including onset, duration, and efficacy of analgesic effects.
Main Results:
- Both APHC1 and HCRG21 demonstrated significant analgesic abilities, with HCRG21 showing equal efficacy to APHC1 despite a higher 50% effective concentration for TRPV1 inhibition.
- HCRG21 provided sustained analgesia for up to 13 hours post-administration.
- APHC1 exhibited a rapid onset of analgesic action within 5 minutes but lasted for 3 hours.
Conclusions:
- Recombinant Kunitz-type peptides APHC1 and HCRG21 possess distinct pharmacodynamic profiles for TRPV1-mediated analgesia.
- The differing binding mechanisms to TRPV1 likely account for the observed variations in analgesic onset and duration.
- These peptides represent promising candidates for developing novel pain therapeutics targeting the TRPV1 channel.
Related Concept Videos
Thermosensation
Mechanically-gated Ion Channels
Analgesia and Pain Management
Non-gated Ion Channels
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
Nociception
Pain


